TMCnet News

CRWE.OB, SMMF, & ONXX: Onyx Eyes FDA Filing for Blood Cancer Drug
[July 26, 2010]

CRWE.OB, SMMF, & ONXX: Onyx Eyes FDA Filing for Blood Cancer Drug


CROWN EQUITY HLD (OTC BB: CRWE.OB) Last: $0.36 Recent News: Crown Equity Holdings, Inc. Expands to Germany LAS VEGAS, July 22, 2010 (GLOBE NEWSWIRE) -- Crown Equity Holdings Inc. (OTCBB:CRWE - News) announced today that it has added a company known as PenStox.com, a German Small Cap Service Provider led by Lars Schmidt, to its CRWENewswire.com team. PenStox.com will moderate the German CRWEnewswire websites in Germany.



Crown Equity Holdings plans to add more European companies to its CRWEnewswire network.

About CRWE: CRWEPicks.com is an independent electronic publication that provides information on selected publicly traded companies. CRWEPicks.com is not a registered investment advisor or broker-dealer.


CRWEPIcks.com and Crown Equity Holdings, Inc., affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

We encourage investors to join the FREE e-mail alerts by visiting: http://www.crwepicks.com or sending an e-mail to [email protected].

Visit: http://www.crownequityholdings.com ______________________________ Summit Financial Group, Inc. (SMMF) Summit Financial Group is a financial holding company which provides community banking and insurance services . Summit's community banking operations consist of 15 banking offices located in the Eastern Panhandle and South Central regions of West Virginia and in the Shenandoah Valley and Northern regions of Virginia.

Summit Financial Group Inc.'s affiliate entities are: Summit Community Bank, a state chartered community bank , and Summit Insurance Services, LLC, a full lines insurance agency.

______________________________ Recent News: Onyx Eyes FDA Filing for Blood Cancer Drug Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally. Its lead product includes Nexavar (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis. This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals. Its developing products include Nexavar for the treatment of liver cancer, kidney cancer, non-small cell lung cancer, thyroid cancer, breast cancer, ovarian cancer, and colorectal cancer; and Carfilzomib for the treatment of multiple myeloma and solid tumor.

http://www.onyx-pharm.com ******************************************* Sign-Up For Free Stock Alerts At http://crwepicks.com/signup ******************************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.

*******************************************

As a community-building service, TMCnet allows user submitted content which is not always proofed by TMCnet editors. If you feel this entry is of inferior quality or wish to report it for some reason, please forward the URL to "webedit [AT] tmcnet [DOT] com" with your comments.


[ Back To TMCnet.com's Homepage ]